2. Neuronal Signaling
  3. Glucosylceramide Synthase (GCS)
  4. Ibiglustat succinate

Ibiglustat succinate  (Synonyms: Venglustat succinate; SAR402671 succinate; GZ402671 succinate)

Cat. No.: HY-16743B Purity: 99.71%
COA
SDS
Handling Instructions Technical Support

Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.

For research use only. We do not sell to patients.

CAS No. : 1629063-80-4

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
2 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Ibiglustat succinate:

Ibiglustat succinate Related Antibodies

Top Publications Citing Use of Products
Cell Proliferation/Viability Assay
Flow Cytometry
WB
IF
Histological Imaging/Staining

    Ibiglustat succinate purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Dec 2:285:138303.  [Abstract]

    CCK-8 assay evaluating the proliferation of PK-15 cells treated with UGCG inhibitors Ibiglustat (1.6-1000 nM) over 12-36 h.

    Ibiglustat succinate purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Dec 2:285:138303.  [Abstract]

    Flow cytometry analysis of PRV-GFP infection in PK-15 cells pretreated with UGCG inhibitors Eliglustat hemitartrate (1.6–1000 nM) and Ibiglustat (1.6–1000 nM) for 3 h, followed by GFP fluorescence intensity measurement 24 h post-infection to assess viral replication. The results showed that Ibiglustat significantly reduced PRV-GFP fluorescence signals in a dose-dependent manner.

    Ibiglustat succinate purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Dec 2:285:138303.  [Abstract]

    Ibiglustat (1.6–1000 nM; pretreated 3 h) reduced PRV-gB protein levels in a dose-dependent manner in PRV-QXX-infected PK-15 cells.

    Ibiglustat succinate purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Dec 2:285:138303.  [Abstract]

    Ibiglustat (1.6–1000 nM; 3 h) reduced PRV-gB protein levels in a dose-dependent manner in PRV-QXX-infected PK-15 cells.

    Ibiglustat succinate purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2024 Dec 2:285:138303.  [Abstract]

    Brain, lung, liver, and spleen injury were assessed using hematoxylin and eosin staining 3 days post-infection (n = 3 per group). Histopathological examination revealed that PRV infection in mice induced proliferation of brain microglial cells, inflammatory cell infiltration in the lungs, significant thickening of alveolar septa, vacuolar degeneration of liver cells, and inflammatory tissue damage in the spleen. These pathological changes were attenuated by treatment with the UGCG inhibitors, Eliglustat hemitartrate or Ibiglustat ((2.5 mg/kg); s.c.; once daily for the first 3 days of PRV infection). Scale bar = 50 μm.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].

    In Vitro

    Ibiglustat (SAR402671) succinate (1 μM, 15 days; Fabry disease (FD) cells) is close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat succinate can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes[4].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Ibiglustat succinate Related Antibodies
    Molecular Weight

    507.57

    Formula

    C24H30FN3O6S
    CAS No.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C.OC(CCC(O)=O)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 250 mg/mL (492.54 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9702 mL 9.8509 mL 19.7017 mL
    5 mM 0.3940 mL 1.9702 mL 3.9403 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    Purity & Documentation
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9702 mL 9.8509 mL 19.7017 mL 49.2543 mL
    5 mM 0.3940 mL 1.9702 mL 3.9403 mL 9.8509 mL
    10 mM 0.1970 mL 0.9851 mL 1.9702 mL 4.9254 mL
    15 mM 0.1313 mL 0.6567 mL 1.3134 mL 3.2836 mL
    20 mM 0.0985 mL 0.4925 mL 0.9851 mL 2.4627 mL
    25 mM 0.0788 mL 0.3940 mL 0.7881 mL 1.9702 mL
    30 mM 0.0657 mL 0.3284 mL 0.6567 mL 1.6418 mL
    40 mM 0.0493 mL 0.2463 mL 0.4925 mL 1.2314 mL
    50 mM 0.0394 mL 0.1970 mL 0.3940 mL 0.9851 mL
    60 mM 0.0328 mL 0.1642 mL 0.3284 mL 0.8209 mL
    80 mM 0.0246 mL 0.1231 mL 0.2463 mL 0.6157 mL
    100 mM 0.0197 mL 0.0985 mL 0.1970 mL 0.4925 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Ibiglustat succinate Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Ibiglustat1629063-80-4VenglustatSAR402671GZ402671SAR 402671SAR-402671GZ 402671GZ-402671Glucosylceramide Synthase (GCS)GBAmutationsoralGL-3 levelsFabry diseaseParkinson's diseaseInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ibiglustat succinate
    Cat. No.:
    HY-16743B
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.